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ABSTRACT
Herpes simplex virus type 1 (HSV-1) has been associated with pulmonary disease, mostly in severely
immunocompromised patients. After reactivation and shedding in the oropharynx, the virus may reach
the lower respiratory tract by aspiration or by contiguous spread. HSV-1 can be detected in clinical
specimens by virus culture or quantitatively by nucleic acid ampliﬁcation techniques. With these
techniques, HSV-1 is often detected in the respiratory secretions of critically-ill patients. However, a
clear diagnosis of HSV-1 pneumonia is difﬁcult to establish because clinical criteria, radiological features
and laboratory ﬁndings all lack speciﬁcity. Lower respiratory tract HSV-1 infections have not been
associated with speciﬁc risk-factors. There is also an absence of consistent data concerning the effect of
antiviral treatment on the outcome of critically-ill patients. Further studies are needed to better deﬁne
the pathogenic role of HSV-1 in the lower respiratory tract of these patients, to improve the diagnosis,
and, especially, to assess the need for antiviral treatment in the individual patient.
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INTRODUCTION
Herpes simplex virus type 1 (HSV-1) causes a
variety of infections that involve mucocutaneous
surfaces, the central nervous system and, occa-
sionally, visceral organs such as the lung [1,2].
The virus has been reported to be associated with
pulmonary disease since 1949 [3], but until two
decades ago, HSV pneumonia was considered to
be rare. This diagnosis was usually based on
autopsy ﬁndings [4–11]. The more frequent use of
ﬁbreoptic bronchoscopy and bronchoalveolar
lavage (BAL) in recent years has resulted in the
virus being isolated with increasing frequency
from respiratory secretions. This has been paral-
leled by an increase in the frequency of the
diagnosis of HSV tracheobronchitis or pneu-
monia, mostly in immunocompromised hosts
[12–19]. However, the signiﬁcance of the presence
of HSV-1 in respiratory secretions from these
patients, and especially from mechanically-venti-
lated patients, is still a topic for debate. This
review focuses on the potential clinical
importance of HSV-1 respiratory infections in
critically-ill patients, with special reference to the
controversies in the literature concerning patho-
genesis, clinical spectrum, risk-factors and
response to antiviral therapy.
THE CAUSATIVE AGENT
HSV-1 can infect nearly every mucocutaneous
and visceral site in the human body. Infections
with HSV in humans have been described since
ancient Greek times [20,21]. The word herpes,
which means to creep or to crawl, is found in the
original Greek description of the appearance of
spreading skin lesions [22]. Clinical descriptions
Corresponding author and reprint requests: A. M. Simoons-
Smit, VU University Medical Center, Medical Microbiology
and Infection Control, PO Box 7057, 1007 MB Amsterdam, The
Netherlands
E-mail: am.simoons@vumc.nl
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
of herpes labialis go back to the time of Hippo-
crates [21]. Early in the 20th century, the virus
was transmitted successfully from humans to
various animals. The virus was cultured in rabbit
testicular tissue as early as 1925, isolated in chick
embryos in 1940, and grown successfully in
conventional tissue culture systems about
15 years later [21]. The histological association of
herpes virus infection with the formation of
multinucleated giant cells with intra-nuclear
inclusions was ﬁrst described in 1934 [23].
HSV-1 is classiﬁed in the a-herpes virus group
of the Herpesviridae, together with HSV type 2
(HSV-2) and varicella-zoster virus. All herpes
viruses possess an internal core with a single
large, linear, double-stranded DNA molecule, an
icosahedral capsid with 162 capsomeres, and a
lipid envelope. HSV-1 encodes at least 80 different
structural and non-structural polypeptides, inclu-
ding ten different glycosylated proteins. The
predominant antibody response to HSV infection
is raised against these surface glycoproteins.
There is extensive cross-reactivity among the
different glycoproteins of HSV-1 and HSV-2.
Therefore, differentiation between HSV-1 and
HSV-2 infections in commercial antibody assays
is not possible. Type-speciﬁc antibody assays
based on glycoprotein G1 (gG1) for HSV-1 and
glycoprotein G2 (gG2) for HSV-2 exist, but are
used rarely in routine diagnostic laboratories. The
virus structure, function and biological properties
have been extensively described previously [2,24–
26].
PATHOGENESIS
HSV infections are very common in the human
population. Primary HSV infections are usually
asymptomatic, but can manifest as gingivostoma-
titis or pharyngitis [1,2]. Following initial acqui-
sition, HSV-1 establishes latency and remains in a
non-replicating form in sensory ganglia for life,
commonly in the trigeminal ganglia, but the virus
has also been isolated from the superior cervical
and vagus ganglia [27,28].
Depending on age (> 5 years) and socio-econo-
mic status, 40–98% of the human population in
different countries has antibodies to HSV-1 [29–
32]. Despite the presence of these antibodies, the
virus reactivates intermittently, following local
stimuli (e.g., tissue lesion or UV light) or systemic
stimuli (e.g., fever, hormonal imbalance or
impairment of the immune system during emo-
tional stress or surgery). Reactivation of HSV-1
has been associated with asymptomatic virus
excretion in saliva [33–36], ulceration of the
mouth mucosa or herpes labialis [37–40], or more
serious disease such as herpetic oesophagitis
[10,41,42], tracheobronchitis or pneumonia in
immunocompromised hosts [4,11,12,14,16,17,
19,36,43–48]. Because the primary infection is
often asymptomatic, reactivation can be the ﬁrst
clinical manifestation of infection.
Classically, HSV-1 infects squamous epithelium
[4,36]. Factors promoting squamous metaplasia,
such as trauma, smoking, burns, radiation ther-
apy or chemotherapy, are mentioned in several
studies as predisposing the patient to lower
respiratory tract infection by HSV [36,46,49].
However, metaplasia may also occur as a secon-
dary response to the infection itself, as the virus is
known to cause cytotoxic changes in the respir-
atory mucosa, with disruption of the protective
mucociliary surface [12]. It has also been suggest-
ed that intubation, instrumentation and mechan-
ical trauma of the airways predispose to herpetic
pulmonary infections [5,6,9,45]. Airway trauma is
likely to make the trachea more susceptible to
infection with HSV by permitting the virus to
migrate from the oral cavity to the trachea by
contiguous spread [11]. However, not all patients
from whom HSV-1 is isolated from the lower
respiratory tract are intubated [12,36,43].
HSV-1 may reach the lower respiratory tract by
three different routes. Contiguous spread to the
lung parenchyma, or aspiration of the virus in
patients shedding the virus from mucocutaneous
or oropharyngeal lesions, may play a role in many
cases [6]. Focal necrotising pneumonitis has been
suggested to result from this local spread [11,50].
Dislodgement of infected particles from the
mucous adhesive layer inside the endotracheal
tube, followed by their migration to the lower
airways, may also contribute to this mechanism
[51]. The concept of haematogenous seeding is
supported by Ramsey et al. [11], and is thought to
lead to diffuse interstitial pneumonia. Recovery of
HSV from circulating lymphocytes or peripheral
buffy coat blood cells provides support for this
hypothesis [36,52]. A third mechanism, namely
reactivation of latent infection within the vagal
ganglion, with spread along the vagus nerve to
the lung epithelium, has also been postulated [43].
This suggestion is supported by the isolation of
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HSV from the jugular portion of the vagus
ganglion in cadavers [27]. The precise way in
which HSV-1 migrates from ganglia to epithelium
is not understood, and the exact contribution of
each of the three pathogenic mechanisms,
although all three are plausible, remains un-
known.
Both humoral and cell-mediated immunity are
involved in the response to HSV-1 infection [26].
The initial stage of HSV-1 infection is inﬂuenced
by natural killer cells and type 1 and 2 cytokines.
Once infection of epithelial cells takes place,
neutralising antibodies are ineffective and T-cell
immune responses prevail [52,53]. The most
severe HSV-1 disease occurs in immunocompro-
mised patients, suggesting that T-cell-mediated
immunity is very important in the control and
resolution of recurrent HSV-1 infection. Thus,
viral reactivation might be an index of the
depression of the host immune response. The
various alterations in cell-mediated immunity in
response to the HSV-1 antigen have been assessed
by reduced skin reactivity, decreased T-lympho-
cyte counts and T-cell subsets, impaired lympho-
cyte transformation, reduced lymphokine
production, decreased natural killer cell activity,
and ⁄ or decreased cytokine production [54–58].
Although rare, nosocomial transmission of
HSV-1 from patient to patient, and from patient
to healthcare worker, has been reported [33,59–
61]. The source of these hospital and occupational
infections is usually found to be HSV-1-positive
respiratory secretions of patients. Full compliance
with infection control measures in the case of
contact with secretions of HSV-positive patients is
therefore important.
CLINICAL FEATURES AND
INCIDENCE
Primary infection with HSV-1 usually occurs in
early childhood and in young adulthood. The
initial infection can be asymptomatic or give rise to
combinations of fever, sore throat, gingivostoma-
titis, localised lymphadenopathy, anorexia and
malaise [1,2,24]. After the primary infection, the
virus can reactivate from its latency, leading to
asymptomatic excretion in saliva or to intra-oral
mucosal ulceration or oro-labial lesions. The fre-
quency of recurrences varies among individuals.
HSV infection of the upper respiratory tract is a
common, usually self-limiting, disease. In studies
among university students, infections with HSV-1
were associated with 6–12% of acute respiratory
illnesses [35,62]. HSV-1 has also been described as
the cause of prolonged acute laryngotracheo-
bronchitis [63]. In contrast, HSV infection of the
middle and lower respiratory tract in adults is
thought to occur rarely, and is diagnosed almost
exclusively in immunocompromised patients. In
1949, Morgan and Finland ﬁrst suggested that
HSV could be a respiratory tract pathogen, and
reported the post-mortem isolation of ‘a strain of
herpes virus’ from the lung of a patient with an
atypical pneumonia [3]. Despite many reports of
HSV-1 and lower respiratory tract infections since
that time, the true incidence remains unknown. In
the 1960s and 1970s, according to Tuxen [64], a
total of 66 cases of HSV lower respiratory tract
infections appeared in the literature [3–11,65–69].
The diagnosis was made in only three (4%) living
patients [7,66,69], with the remaining cases being
diagnosed at autopsy.
Following the initial observation of Morgan
and Finland, it was 1965 before Cheever et al. [65]
reported a patient with Hodgkin’s disease and
HSV inclusions in biopsy specimens from the
tongue, oesophagus, upper respiratory tract and
lungs. Four large-scale autopsy studies during the
period 1966–1982, in which nearly 9000 autopsies
were examined for the presence of HSV in the
trachea, bronchi or lungs [4,6,10,11], enabled
Tuxen [64] to calculate that the incidence of
HSV lower respiratory tract infections was as
low as 0.5%. Most patients in these studies were
intubated, or severely immunocompromised, be-
cause of major burns or underlying malignancies.
Similarly, the case reports and studies on small
series of patients with lower respiratory tract
infections reported during the 1970s associated
detection of HSV with severe immunosuppres-
sion and with high mortality [5,7–9,41,42,66–69].
For example, Nash and Foley [5] identiﬁed 15
patients with herpetic involvement of the lower
respiratory tract, 14 of whom had burn injuries.
In recent years, studies have focused on critic-
ally-ill patients. Tuxen et al. [43] described the
ﬁrst large prospective series of patients in whom
HSV involvement of the lower respiratory tract
had been diagnosed in living patients. HSV-1 was
found in the tracheobronchial secretions of 14
(30%) of 46 patients with adult respiratory dis-
tress syndrome (ARDS), whereas no case was
diagnosed among mechanically-ventilated
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patients without ARDS. Isolation of HSV-1 was
associated with prolonged ventilator support and
increased mortality. An even higher incidence of
62% was found by the same author in 1987 in a
study of the prophylactic use of acyclovir in lower
respiratory tract infections in critically-ill patients
with ARDS [56]. Nearly all patients for whom the
isolation of HSV from the lower respiratory tract
has been reported since that time have been
immunocompromised or critically-ill patients
undergoing immunosuppressive therapy [70],
organ transplantation [71,72], or major surgery
[16,44,47,73–75]; patients with malignancies
[76,77], severe trauma [17,78], or burns [48,58];
or patients who have stayed in an intensive care
unit (ICU) [14,19,45,46,79]. Table 1 summarises a
number of these studies. The incidence of HSV-1
in respiratory specimens varies between 2% and
50%, but these studies are difﬁcult to compare
because of large differences in study design,
study populations and ⁄ or diagnostic methods.
Only a few cases document HSV pneumonia in
immunocompetent patients [36,81–84], patients
with no previous history of chronic lung disease
[12], or patients following general surgery [74]. In
a retrospective study of the clinical features and
disease course of 22 critically-ill patients with
HSV-1 isolated from BAL ﬂuid [85], there were no
signs of more frequent or more severe lung injury
or ARDS in non-surviving than in surviving
patients. The absence of a more complicated
disease course, in combination with the absence
of interstitial radiographical abnormalities and
bronchoscopic airway disease at bronchoscopy, in
these critically-ill patients argues against the
pulmonary pathogenicity of HSV-1.
Unfortunately, there are few prospective stud-
ies of HSV infection. A recent prospective study
by Bruynseels et al. [19] of 764 ICU patients
showed that the prevalence of HSV-1 in the
upper respiratory tract is as high as 22% in
critically-ill patients, compared with 2–3% in
healthy volunteers and patients not admitted to
the ICU. HSV-1 was detected in lower respiratory
tract specimens from 39% of patients with HSV-1
in their throat, and in 5% of patients with an
HSV-negative throat. Of the patients with ARDS,
> 40% had HSV-1 in the throat, and HSV-1 was
isolated from the lower respiratory tract in 20% of
cases. It was concluded that HSV-1 in the throat is
an independent risk-factor for the development of
lower respiratory tract infection with HSV. Whe-
ther HSV-1 reactivation or infection could trigger
the subsequent development of ARDS, or whether
ARDS was present before the isolation of HSV-1,
remains unclear. In the context of a possible
association of HSV-1 with ARDS, it is remarkable
that a study examining the diagnostic value of
open lung biopsies in patients with ARDS found
only one case of HSV-1 pneumonia among 36
patients [86].
DIAGNOSIS
The diagnosis of HSV pneumonia in immuno-
compromised hosts, as well as in immunocompe-
tent patients, is difﬁcult because clinical criteria,
laboratory ﬁndings and radiological features all
lack speciﬁcity. Therefore, HSV infection can be
Table 1. Summary of clinical studies of herpes simplex virus (HSV) respiratory infections in critically-ill patients (adapted
from [80])
Year Ref.
HSV-positive
patients
Incidence
% (95% CI) Method(s) Setting Design Manifestation Risk-factors Mortality
1982 [43] 14 ⁄ 46 30 (19–45) Cy, I, C, S, H ARDS Prosp Tracheobronchitis Not studied 57%
1988 [12] 9 ⁄ 9 – H, C, IHC, B Bronchospasm Retrosp Tracheobronchitis Not studied 0%
1992 [14] 37 ⁄ 308 12 (9–16) BAL, C, Cy, S Pulmonary infection Prosp Pulmonary inﬁltrate Intubation 24%
1993 [45] 42 ⁄ 42 – C Various Retrosp Tracheobronchitis Intubation 57%
1995 [16] 3 ⁄ 6 50 (19–81) C, BAL, Cy Post-thoracotomy Retrosp Pneumonia Immunosuppression 0%
1995 [15] 53 ⁄ 1199a – C, BAL Immunosuppression Retrosp Pneumonia Intubation 21%
1996 [72] 6 ⁄ 245 2 (1–5) C, IF, BAL Liver transplantation Retrosp Pneumonia Immunosuppression 17%
1998 [73] 8 ⁄ 142 6 (3–11) C, BAL Surgical ICU Retrosp Fever, lymphopenia Thrombocytopenia 63%
2000 [17] 4 ⁄ 74 5 (2–13) C, B Trauma Retrosp Pulmonary inﬁltrate – 27%
2003 [74] 11 ⁄ 104 10 (6–18) C, S ICU > 5 days Prosp Occult None 7%
2003 [19] 58 ⁄ 361b 16 (13–20) C, BAL ICU > 3 days Prosp – HSV in throat 38%
2004 [79] 106 ⁄ 393 27 (23–32) PCR ICU Prosp – APACHE II, age 41%
aData refer to the number of BAL specimens investigated.
bData refer to the incidence of HSV isolation from the lower respiratory tract.
H, histology; C, culture; Cy, cytology; IHC, immunohistochemistry; I, direct immunoﬂuorescence; S, serology; B, bronchoscopy; BAL, bronchoalveolar lavage; APACHE, Acute
Physiology, Age and Chronic Health Evaluation score; ARDS, adult respiratory distress syndrome; ICU, Intensive Care Unit. Prosp, prospective study; Retrosp, retrospective
study.
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missed easily, both clinically and at autopsy
[5,11,36].
Clinical manifestations
Fever, productive cough, dyspnoea, broncho-
spasm and ⁄ or chest pain are mentioned as the
most frequent clinicalmanifestations ofHSV lower
respiratory tract infection, although none of these
symptoms is speciﬁc. Symptoms might also be
overshadowed by the underlying disease of the
patient. Herpes labialis or oropharyngeal lesions
do occur in critically-ill patients and can be quite
extensive [11,36]. These symptoms can precede or
coincide with the onset of HSV-1 pneumonia in
such patients, but a direct relationship with these
manifestations is not yet clear [12,43].
Bronchoscopy and lung biopsy
Bronchoscopy allows direct inspection of the
respiratory epithelium. Local or diffuse tracheal
or tracheobronchial oedema, erythema, mucopu-
rulent secretions, ulcers or a thick, ﬁbrinous
exudative membrane have all been observed in
association with HSV-1 [12,14,45,47,49,56], but
bronchoscopic examination can also be normal
[36,54].
Lung biopsy is unreliable, and may be hazard-
ous in critically-ill patients. Ramsey et al. [11] did
not ﬁnd herpes virus, either by histological exam-
ination or by culture, in open lung biopsy speci-
mens of six critically-ill patients, although HSV
was isolated from lung tissue at autopsy. Similar
results have been described for a patient in whom
anopen lung biopsy specimen showedno evidence
of HSV by histology or culture, despite diffuse
bilateral inﬁltrates, an increase in serum antibody
titres, and bronchoscopic cultures that were posit-
ive for HSV-1 [70]. Papazian et al. [86] performed
open lung biopsies for patientswithARDS [86]. An
unexpectedly high number of cases of cytomega-
lovirus pneumonia were diagnosed, but only one
case of HSV-1 pneumoniawas found. A transbron-
chial biopsy might offer an alternative approach,
but has limited utility, considering the small size of
the tissue specimens that are obtained.
Radiological ﬁndings
Aquino et al. [87] described the characteristics of
chest radiographs of 24 patients with HSV-1
pneumonia. Most patients had a combination of
segmental and sub-segmental mixed ground-
glass opacities and scattered areas of consolid-
ation on the chest radiograph, compatible with a
diffuse and multifocal distribution of parenchy-
mal disease. Pleural effusions were also quite
common. In a retrospective study [88] of 17
patients with HSV-1 pneumonia, bilateral lobar
or diffuse lung opacities were the main ﬁndings
on the chest radiograph. Unilateral consolidation,
large zones of atelectasis and signiﬁcant amounts
of pleural ﬂuid were observed less frequently.
Thus, a characteristic radiographical pattern for
HSV-1 pneumonia was not found.
Laboratory diagnosis
Laboratory methods used to detect HSV include
virus isolation, microscopy, detection of HSV
DNA by PCR, and serology. Virus isolation
remains the reference method [89]. Virus isolation
in cell culture is speciﬁc, relatively inexpensive,
and provides a virus strain that can be typed. A
discernible cytopathic effect in tissue culture
usually develops within 24–48 h of inoculation.
However, the simple isolation of HSV-1 from
respiratory secretions does not differentiate be-
tween true infection and a carrier state, since
asymptomatic shedding does occur, especially in
(critically) ill patients [19,36,50,90,91]. To solve
this diagnostic problem, quantitative viral culture
has been suggested [47], but no studies have
evaluated this possibility to date.
Cytological examination is less sensitive than
virus culture, but can be used to demonstrate
actual tissue involvement. The characteristic fea-
tures of HSV infection are the presence of multi-
nucleated cells with ground-glass intra-nuclear
changes and Cowdry type A intra-nuclear inclu-
sion bodies in the affected tissues [36,43]. Detec-
tion of these histological hallmarks of HSV tissue
infection is quite speciﬁc for true lower respirat-
ory tract infections [5,6,69,92,93]. The speciﬁcity of
both cytological examination and virus culture is
increased further if samples are taken by BAL.
However, the nuclear changes typical of HSV
infection were detected in only one-third of
patients with severe respiratory disease and
positive HSV-1 BAL specimens [14]. In contrast,
cytology with typical HSV changes was observed
in all patients with herpetic tracheobronchitis by
Sherry et al. [12].
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Several methods for the rapid detection of HSV
antigen directly in infected tissue have been
developed. These include the use of polyclonal
and ⁄ or monoclonal antibodies, and their detec-
tion by microscopical observation of immunoﬂu-
orescence, immunoperoxidase staining and ⁄ or by
ELISA. In combination with tissue culture, these
antigen detection methods increase the speed of
diagnosis by allowing the detection of HSV before
an overt cytopathic effect is seen [50].
HSV DNA can be detected with a high degree of
sensitivity and speciﬁcity with nucleic acid ampli-
ﬁcation by PCR. Primers and probes can be direc-
ted at sequences that are conserved among both
HSV-1 and HSV-2, or type-speciﬁc primers can be
used in a multiplex PCR or in separate PCR
ampliﬁcations [94]. In recent years, nested PCR
and real-time PCR techniques have been devel-
oped with analytical sensitivities of 1–100 copies
[95–98]. Real-time PCR offers the opportunity to
determine the HSV viral load. However, studies
evaluating these methods for diagnosing HSV
pneumonia have not yet been published. Gerardts
et al. [83] diagnosed HSV pneumonia post mortem
by PCR and electron-microscopy in a patient for
whom virus culture of the lung tissue remained
negative. Amajor drawback of using PCR to detect
HSV is that this test detects the presence of HSV
DNA, but does not determine whether there is
active infection, i.e., active viral replication. True
infectionmight be detected by relating the quantity
of HSVRNA to the number of parenchymal cells in
standardised BAL specimens, or by determining
the ratio of HSVDNA toHSVRNA as ameasure of
replication of the virus. Studies to evaluate the
validity of such approaches are needed.
Serology is not helpful for diagnosing acute
HSV respiratory infections. Among healthy
adults, > 90% have neutralising antibodies to
HSV, and serological tests available routinely
cannot differentiate reliably among primary,
recurrent and past HSV-1 infections [89]. During
herpetic tracheobronchitis, no predictable rise in
titres was observed by Sherry et al. [12], although
a signiﬁcant rise in titre (‡ 4-fold) was found in
58% of patients with HSV-1 lower respiratory
tract infection [14].
Pulmonary leakage
In order to evaluate tissue injury caused by HSV-
1, the pulmonary leak index was measured in
four mechanically-ventilated patients from whom
HSV-1 was isolated from tracheal aspirate or BAL
ﬂuid [99]. All patients had pulmonary inﬁltrates,
but a normal pulmonary permeability, as meas-
ured by the pulmonary leak index. This ﬁnding
does not support the concept of a role for HSV-1
as a causative agent of pneumonia in critically-ill
patients from whom the virus is isolated from
respiratory secretions, but suggests harmless
shedding of the virus.
RISK-FACTORS AND OUTCOME
Whether HSV causes or contributes to increased
morbidity or mortality in patients with lower
respiratory tract infections, or whether it is merely
an epiphenomenon in a more severely-ill host, is
uncertain. Most patients described in the litera-
ture had serious underlying disease. The predis-
posing conditions in adults with lower
respiratory tract HSV infections include ARDS
[14,43], burns [5,6,48,58,67], organ transplantation
[7,11,66,71], neoplasms [4,6,9,36,69], alcoholism
[68], renal failure [6] and aplastic anaemia [11].
Pregnancy has also been mentioned as a predis-
posing factor [5].
A recent study demonstrated a signiﬁcant
reduction in hospital survival among patients
receiving assisted ventilation who were shedding
HSV-1 compared with non-shedders (40.6% vs.
24.4%, respectively) [79]. Old age and high APA-
CHE II scores were risk-factors for HSV shedding.
Schuller et al. [45,46] compared immunocom-
petent with immunocompromised critically-ill
patients from whom HSV-1 was recovered
from the respiratory tract. Surprisingly, the clin-
ical manifestations of HSV-1 infection were found
to be more severe in the immunocompetent
patients than in the immunosuppressed patients.
Mortality was also higher in the non-immuno-
compromised group. A history of smoking
tobacco, an older age, endotracheal intubation,
unresolving acute bronchospasm and leukocyto-
sis were all signiﬁcantly more frequent in the non-
immunocompromised group. These data imply
that the pathogenicity of HSV in the respiratory
tract might vary with the underlying immune
status and the local immune response of the host
[45,46]. Whether this difference can be attributed
to HSV-1 per se is not clear.
Mortality rates of up to 63% are found in
clinical studies of HSV respiratory infections in
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critically-ill patients (Table 1). Tuxen et al. [43]
found a mortality rate of 60% in patients with
ARDS from whom HSV-1 was isolated from the
respiratory tract, compared with 45% in patients
with ARDS but without HSV-1. Cook et al. [73]
reported a higher mortality rate in surgical ICU
patients who had HSV-1 (or cytomegalovirus)
respiratory infections, and speculated that herpes
viruses lead to immunosuppression and predis-
pose to subsequent bacterial and fungal infec-
tions. This predisposition to secondary bacterial
or yeast infections as a consequence of HSV
infection has also been suggested previously
[5,10], but Tuxen et al. [43] did not observe such
a relationship.
Bruynseels et al. [19] reported that patients
carrying HSV in the throat have a signiﬁcantly
longer duration of stay in the ICU and a higher
mortality rate when compared with patients
without the virus, although the difference in
mortality appeared to be associated with disease
severity. In contrast, Porteous et al. [100] reported
that oral shedding was not related to outcome in
critically-ill surgical patients. However, according
to this study, mortality associated with HSV-1
shedding was particularly high in patients who
failed to develop a rise in antibody titre.
A retrospective cohort study in the ICU found a
mortality risk of c. 40% in patients from whom
HSV-1 was isolated in BAL ﬂuid, mainly because
of underlying disease and co-morbidity. These
same factors may predispose to endogenous
reactivation of the virus [85]. Therefore, HSV
seems to be a marker, rather than a mediator, of
severe illness. Hence, the isolation of herpes
viruses from the respiratory tract secretions may
be a consequence of harmless reactivation
[91,100], as has been reported for human herpes
virus type 6 in critically-ill patients [101,102].
THERAPY
Acyclovir is the treatment of choice for HSV-1
infection; this compound is effective and has low
toxicity. However, no randomised, placebo-con-
trolled studies are available concerning the effect
of acyclovir on the outcome of critically-ill
patients with signs and symptoms of lower
respiratory tract infection and with HSV-1-posit-
ive respiratory secretions. Although some studies
have reported a successful response to acyclovir
[12,16,44,49,72,75], others have not demonstrated
a clinical beneﬁt [13,45,56,73,103], or did not
evaluate the clinical response to treatment
[14,47]. Sherry et al. [12] treated nine burn patients
with herpetic tracheobronchitis and refractory
bronchospasm, and all showed clinical and
bronchoscopic improvement. Schuller et al. [45]
found no difference in mortality, duration of
mechanical ventilation, or length of stay, between
patients who received acyclovir and patients who
were not treated. Prellner et al. [14] reported 37
immunocompromised hosts with severe airway
infection and proof of HSV in BAL ﬂuid, nine of
whom died, including seven who were treated
with acyclovir. Tuxen et al. [56] showed that
prophylactic administration of acyclovir lowered
the incidence of HSV, but failed to alter patient
outcome. HSV-1 was isolated from the respiratory
tract of one of 17 ARDS patients, and from 15 of 21
placebo-treated ARDS patients. It was concluded
that HSV is not a signiﬁcant pathogen in the lower
respiratory tract and should be treated only if: (1)
it occurs in immunocompromised patients (e.g.,
patients with malignancies, burns, or who have
received cytotoxic therapy); (2) there is evidence
of pulmonary parenchymal invasion; or (3) there
is unexplained clinical deterioration.
At present there are no guidelines for the
treatment of HSV infection in critically-ill patients
who are not immunocompromised. Despite this,
it will be difﬁcult to withhold antiviral treatment
from a critically-ill patient with general signs of
infection, extensive mucosal herpes infection,
focal or diffuse inﬁltrates on the chest radiograph,
a positive test for HSV-1, and no other causative
microorganism.
CONCLUSIONS
Although the isolation of HSV-1 from the respir-
atory tract of critically-ill patients is reported with
increasing frequency, the signiﬁcance of this
ﬁnding remains unclear. This is partly because
of the large differences in study populations,
study designs, diagnostic tools and case deﬁni-
tions among the various studies to date. The
major obstacle to understanding the role of HSV-1
in lower respiratory tract infections is the lack of a
clinically-useful diagnostic reference standard
that is able to differentiate between the presence
of reactivated HSV-1 as an innocent bystander
and a clinically-signiﬁcant infection of the lung
parenchyma by HSV-1 [47]. Whether HSV-1 in the
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lower respiratory tract plays an important role in
the outcome of these critically-ill patients is also
unclear. HSV-1 is often present in the lower
respiratory tract in the absence of inﬂammation,
and the illness caused by HSV has rarely been a
reason for hospitalisation [36]. Routine prophy-
laxis in critically-ill patients is not recommended,
and treatment with antiviral agents should be
discouraged while the pulmonary pathogenicity
of HSV-1 in mechanically-ventilated patients is
unclear. However, there are situations in which
tentative treatment of the critically-ill patient with
acyclovir may be justiﬁed.
In conclusion, the respiratory pathogenicity of
HSV-1 in the critically-ill patient is at least
doubtful. Prospective studies with clearly deﬁned
study populations and study methods, including
quantitative molecular diagnostic procedures for
properly standardised respiratory specimens, are
needed to answer the question of whether the
virus is able to replicate in the lung tissue and is
thereby responsible for tissue damage.
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